The research was led by the National Center for AIDS/STD Control and Prevention of the China CDC and completed jointly by multiple agencies and organizations. The project won the first prize at the Science and Technology Awards of the Chinese Preventive Medicine Association and the first prize at the Beijing Science and Technology Progress Awards in 2019.
The research revealed the transmission and evolution of the major HIV strains in China, identified seven new widespread recombinant strains (CRF) which have been proved to drive the continuous spread of the AIDS epidemic in China. It also led to the establishment of a WHO regional drug resistance lab and provided technology support for neighboring and African countries.
The research monitored the variation pattern of drug resistance strains, revealed the occurrence sequence of drug resistance and demonstrated that reducing drug resistance in the first year could significantly reduce mortality rates. It identified the vaccine strain candidate and obtained super-spectrum monoclonal antibodies that could neutralize more than 90% of HIV strains around the world.
This project provided technological support for AIDS diagnosis and treatment and for vaccine development.
It generated five patents, one professional diagnostic standard, one technical guide and one monograph, in addition to 283 SCI papers published during its implementation.